Author:
El Kebbi Ola,Prather Cassandra S.,Elmuti Lena,Khalifeh Malak,Alali Muayad
Abstract
AbstractExisting literature on febrile neutropenia (FN) has categorized patients with acute leukemia or those undergoing allogeneic stem cell transplantation (SCT) as being high risk for severe infection, bacteremia, and poor outcomes. Comprehensive studies of infection risk in pediatric high-risk neuroblastoma (NB-HR) during induction chemotherapy are limited, and mostly merged within the solid tumor (ST) group. Therefore, it is unclear whether infectious complications and outcomes for NB-HR are the same as in other ST groups. We conducted a retrospective medical record review of pediatric FN patients in a single center from March 2009 to December 2016. FN episodes were categorized into five groups based on underlying diagnosis (acute myelogenous leukemia (AML), acute lymphocytic leukemia (ALL), NB-HR during induction chemotherapy, other solid tumors, and SCT). Comparative analyses of infectious complications between patients with NB-HR and those with other types of cancer diagnoses were performed. A total of 667 FN episodes (FNEs) were identified in 230 patients. FNEs occurred in 82 episodes with NB-HR. Bloodstream infection (BSI) occurred in 145 (21.7%) of total FN episodes. The most isolated organisms were the viridians group streptococci (VGS) (25%). NB-HR patients have higher rates of VGS bacteremia (OR 0.15, 95% [CI 0.04, 0.56]) and are more likely to be admitted to the Pediatric Intensive Care Unit (PICU) compared to patients with other solid tumors (OR 0.36, 95% [CI 0.15, 0.84]). Interestingly, there is no difference in VGS rates between patients with NB-HR and those with AML despite the fact that NB-HR patients do not receive a cytosine arabinoside (AraC)-based regimen. This large neuroblastoma cohort showed that patients with NB-HR during induction chemotherapy are at higher risk for VGS bacteremia and PICU admissions compared with patients with other solid tumors. Further prospective studies are needed to investigate infection-related complications in this high-risk group and to improve morbidity and mortality.
Publisher
Springer Science and Business Media LLC
Reference40 articles.
1. Goodman, M. T., Smith, M. A. & Olshan, A. F. Sympathetic Nervous System Tumors. Cancer Incidence and Survival Among Children and Adolescents 35 (United States SEER Program, 1999).
2. Gurney, J. G. et al. Infant cancer in the US: Histology-specific incidence and trends, 1973 to 1992. J. Pediatr. Hematol. Oncol. 19(5), 428–432 (1997).
3. Cohn, S. L. et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG task force report. J. Clin. Oncol. 27(2), 289 (2009).
4. Smith, V. & Foster, J. High-risk neuroblastoma treatment review. Children 5(9), 114. https://doi.org/10.3390/children5090114 (2018).
5. Rogers, A. E. et al. Risk factors for bacteremia and central line-associated blood stream infections in children with acute myelogenous leukemia: A single-institution report. Pediatr. Blood Cancer 64(3), e26254 (2017).